
Bedrijfsnieuws: Alembic Pharmaceuticals
december 22, 2019
Translating…
CBD Olie kan helpen bij artrose. Lees hoe op MHBioShop.com
Huile de CBD peut aider avec l’arthrose. Visite HuileCBD.be
Stocks
| Updated on December 02, 2019 Published on December 02, 2019
Alembic Pharmaceuticals on Monday announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application Diclofenac Sodium Topical Solution USP, 2% w/w. The drug is indicated for the treatment of the pain of osteoarthritis of the knees. Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of $974 million for 12 months ending December 2018, according to IQVIA. Shares of Alembic Pharma closed 0.48 per cent higher at ₹554.90 on the BSE.
Published on December 02, 2019
| Updated on
Alembic Pharmaceuticals on Monday announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application Diclofenac Sodium Topical Solution USP, 2% w/w. The drug is indicated for the treatment of the pain of osteoarthritis of the knees. Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of $974 million for 12 months ending December 2018, according to IQVIA. Shares of Alembic Pharma closed 0.48 per cent higher at ₹554.90 on the BSE.
Published on